معرفی
Professor Jonathon Arnold serves as Director of Preclinical Research and Deputy Academic Director at the Lambert Initiative for Cannabinoid Therapeutics within the Sydney Pharmacy School at the University of Sydney's Faculty of Medicine and Health. With over 140 publications and an h-index of 52, his research program specializes in the discovery and development of cannabis-based medicines through preclinical models of disease.
His primary research interests focus on the efficacy of cannabinoids in epilepsy, sleep disorders, and ageing models, while also exploring the role of the endogenous cannabinoid system in various diseases. Professor Arnold's work spans multiple approaches including animal models, cellular/molecular techniques, and clinical trials, with particular emphasis on behavioral neuroscience, neuropharmacology, and substance abuse and addiction research.
Recent publications demonstrate a strong trend toward translational research, with significant focus on cannabidiol formulations, pharmacokinetics, and clinical applications for neurological conditions. His team has produced numerous studies examining the anticonvulsant properties of various cannabinoids using sophisticated mouse models of epilepsy, particularly Dravet syndrome.
- Animal Ethics Committee 3Rs Award
- Young Investigator Award from the Brain and Behavior Research Foundation 2010 (US)
- Excellence in PhD supervision award from the Sydney Medical School 2011
- Ian Potter Travel Award 2007
- Presentation award at the 1997 International Cannabinoid Research Society meeting
Professor Arnold actively supervises multiple graduate students, having served as primary supervisor for 4 current PhD students and guided 13 PhD students, 2 Masters, and over 30 Honours students to completion. His international collaborations include partnerships with Prof Jacques Micheau at the University of Bordeaux and A/Prof Jennifer Kearney at Northwestern University. The Lambert Initiative research group continues to expand its investigations into psychedelic compounds derived from plants for epilepsy treatment and cannabinoid effects on healthspan extension.
